(Q37458999)

20 August 2017

6 references

13 March 2019

17 June 2019

2 October 2019

19 November 2019

2 September 2020

4 December 2020

0 references

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach (English)

1 reference

20 August 2017

arterial hypertension

5 references

13 March 2019

17 June 2019

2 October 2019

19 November 2019

2 September 2020

1 reference

2 October 2019

1 reference

19 November 2019

1 reference

2 September 2020

antihypertensive drug

1 reference

4 December 2020

R M Nixon

1

1 reference

20 August 2017

E Müller

series ordinal

2

1 reference

20 August 2017

A Lowy

series ordinal

3

1 reference

20 August 2017

H Falvey

series ordinal

4

1 reference

20 August 2017

language of work or name

1 reference

1 May 2009

7 references

International Journal of Clinical Practice

20 August 2017

13 March 2019

17 June 2019

2 October 2019

19 November 2019

2 September 2020

4 December 2020

7 references

20 August 2017

13 March 2019

17 June 2019

2 October 2019

19 November 2019

2 September 2020

4 December 2020

63

1 reference

20 August 2017

5

1 reference

20 August 2017

766-775

1 reference

Creative Commons Attribution 2.5 Generic

20 August 2017

6 references

13 March 2019

17 June 2019

2 October 2019

19 November 2019

2 September 2020

on focus list of Wikimedia project

4 December 2020

ScienceSource

0 references

cites work

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Global burden of hypertension: analysis of worldwide data

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

How should meta-regression analyses be undertaken and interpreted?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Comparison of the efficacy and tolerability of telmisartan 40 mg vs. enalapril 10 mg in the treatment of mild-to-moderate hypertension: a multicentre, double-blind study in Taiwanese patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Patient Adherence With Amlodipine, Lisinopril, or Valsartan Therapy in a Usual-Care Setting

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Characteristics of patients with uncontrolled hypertension in the United States.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779985

Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension

2 September 2018

1 reference

12 December 2020

Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults

1 reference

12 December 2020

Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hy

1 reference

12 December 2020

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

12 December 2020

Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension

1 reference

12 December 2020

Angiotensin II antagonists for hypertension: are there differences in efficacy?

1 reference

12 December 2020

Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators

1 reference

12 December 2020

Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension

1 reference

12 December 2020

24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring

1 reference

12 December 2020

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

1 reference

12 December 2020

1 reference

12 December 2020

Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators

1 reference

12 December 2020

Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators

1 reference

12 December 2020

Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension

1 reference

12 December 2020

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

1 reference

12 December 2020

10.1111/J.1742-1241.2009.02028.X

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19392925

1 reference